POST Online Media Lite Edition


Catalyst names EVP, corporate development

Staff writer |
Coral Gables, Fla., USA - September 5, 2014, Coral Gables, Fla., USA - Catalyst Pharmaceutical Partners, Inc., a biopharmaceutical company, appoints David D. Muth to the newly created position, executive vice president, corporate development.

Article continues below

Mr. Muth has more than 35 years of business experience in the biotechnology and pharmaceutical industries. He most recently served, from 2010 to 2014, as the President and CEO of Croma Pharmaceuticals Inc., where he established North American operations, gained approval of and launched 10 Ocular Surgical products, while building a Canadian Ophthalmology sales organization.

Prior to joining Croma, from 2008 to 2010, he was the Global Head of Business Development for Bausch + Lomb's (B+L) (Pharmaceutical Group), where he negotiated numerous transactions including company/products acquisitions and in-licensed a portfolio of programs.

Prior to B+L, he served as the Executive Vice President and Chief Business Officer for Avalon Pharmaceuticals, President and CEO of Osmotica Pharmaceutical Corporation, President and COO of Cengent Therapeutics and Senior Vice President of Business Operations for Nabi Biopharmaceutical, Inc. At Nabi, he established a hematological/oncology commercial organization and launched four products, two of which were Orphan Drugs.

Prior to Nabi, Mr. Muth spent 17 years with Johnson & Johnson in a variety of senior management roles spanning all commercial functions including marketing research, sales, product management, new product development, and corporate development.


What to read next

Catalyst Paper: CEO Richard Garneau to leave
Catalyst: CFO David Smales to resign
Catalyst names Benjamin Duster IV as new chairman of the board